Aevi Genomic Medicine (NASDAQ:GNMX) Trading Down 8.7%

Aevi Genomic Medicine Inc (NASDAQ:GNMX)’s stock price fell 8.7% during trading on Thursday . The stock traded as low as $0.20 and last traded at $0.21, 5,563,658 shares were traded during trading. An increase of 157% from the average session volume of 2,167,779 shares. The stock had previously closed at $0.23.

Separately, ValuEngine upgraded shares of Aevi Genomic Medicine from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

The business has a 50-day moving average of $0.18.

Aevi Genomic Medicine (NASDAQ:GNMX) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. Equities analysts forecast that Aevi Genomic Medicine Inc will post -0.27 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Aevi Genomic Medicine stock. Virtu Financial LLC grew its position in shares of Aevi Genomic Medicine Inc (NASDAQ:GNMX) by 675.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 278,958 shares of the biotechnology company’s stock after purchasing an additional 242,994 shares during the quarter. Virtu Financial LLC owned about 0.43% of Aevi Genomic Medicine worth $55,000 as of its most recent SEC filing. 6.45% of the stock is owned by institutional investors.

Aevi Genomic Medicine Company Profile (NASDAQ:GNMX)

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease.

Read More: Why is the Consumer Price Index (CPI) important?

Receive News & Ratings for Aevi Genomic Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine and related companies with MarketBeat.com's FREE daily email newsletter.